Cover Image
市場調查報告書

酪胺酸蛋白激酶Fyn:開發中產品分析

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 367829
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
酪胺酸蛋白激酶Fyn:開發中產品分析 Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 76 Pages
簡介

本報告提供以酪胺酸蛋白激酶Fyn為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

酪胺酸蛋白激酶Fyn 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發企業

  • AB Science SA
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • ValiRx Plc
  • Zen-Bio, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0802TDB

Summary

According to the recently published report 'Tyrosine Protein Kinase Fyn - Pipeline Review, H1 2017'; Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Proto-oncogene tyrosine-protein kinase Fyn is an enzyme encoded by the FYN gene. It plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1 phosphorylation, activation and targeting to focal adhesions.

The report 'Tyrosine Protein Kinase Fyn - Pipeline Review, H1 2017' outlays comprehensive information on the Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviewsalso reviews key players involved in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 3, 2 and 1 respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Gastrointestinal, Metabolic Disorders, Respiratory, Dermatology, Hematological Disorders, Musculoskeletal Disorders and Women's Health which include indications Alzheimer's Disease, Breast Cancer, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Systemic Mastocytosis, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Asthma, Bile Duct Cancer (Cholangiocarcinoma), Cancer Pain, Crohn's Disease (Regional Enteritis), Depression, Dysthymia, Endometriosis, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Gliosarcoma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypereosinophilic Syndrome, Lymphangioleiomyomatosis, Metastatic Colorectal Cancer, Metastatic Liver Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Metaplasia, Non-Small Cell Lung Cancer, Obesity, Oligodendroglioma, Ovarian Cancer, Pancreatic Cancer, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Primary Progressive Multiple Sclerosis (PPMS), Progressive Supranuclear Palsy, Pulmonary Arterial Hypertension, Recurrent Glioblastoma Multiforme (GBM), Relapsed Multiple Myeloma, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Type 2 Diabetes, Urticaria Pigmentosa (Mastocytosis and Mastocytoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Overview
    • Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Companies Involved in Therapeutics Development
    • AB Science SA
    • AstraZeneca Plc
    • Bristol-Myers Squibb Company
    • ValiRx Plc
    • Zen-Bio Inc
  • Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Drug Profiles
    • dasatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • masitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • saracatinib difumarate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Fyn Kinase for Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit FYN Kinase for Obesity and Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAL-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAL-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Dormant Products
  • Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Discontinued Products
  • Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Product Development Milestones
    • Featured News & Press Releases
      • May 19, 2017: European Medicines Agency Validates Application for Bristol-Myers Squibb's Sprycel (dasatinib) in Children with Chronic Myelogenous Leukemia
      • May 18, 2017: AB Science Announces Refusal of the marketing authorisation for Masipro (masitinib)
      • May 18, 2017: AB Science Presents Phase 3 Data for Masitinib in Amyotrophic Lateral Sclerosis at the European Network For The Cure of ALS Annual Meeting
      • May 17, 2017: AB Science announces that CHMP has adopted a negative opinion for masitinib in indolent systemic mastocytosis, primarily due to GCP inspection findings
      • May 12, 2017: AB Science announces that ANSM requested the temporary suspension of clinical studies conducted in France following deviations from Good Clinical Practice standards
      • Mar 29, 2017: AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years
      • Mar 20, 2017: AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis
      • Mar 07, 2017: AB Science Announces That Frontiers In Aging Neuroscience Publishes A Comprehensive Review On The Future Potential Of Masitinib In Amyotrophic Lateral Sclerosis
      • Mar 06, 2017: AB Science announces completion of patient recruitment for phase 3 study in severe persistent asthma
      • Feb 01, 2017: Bristol-Myers Squibb Announces European Patent Office Decision on Sprycel
      • Jan 11, 2017: ValiRx announces Clinical Trial Update on VAL201
      • Jan 09, 2017: AB Science announces publication in The Lancet of phase 3 clinical trial results demonstrating masitinib is effective and well tolerated in the treatment of adult patients with severe indolent systemic mastocytosis
      • Jan 03, 2017: New Preclinical Data Demonstrate That Masitinib Has An Unexpected Protective Effect On Muscles And Nerves In Amyotrophic Lateral Sclerosis
      • Dec 08, 2016: ValiRx Announces European Patent Granted For Lead Therapeutic Compound VAL201
      • Dec 01, 2016: AB Science will present phase 3 results in severe s ystemic mastocytosis at the Journees Dermatologiques de Paris 2016
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indications, H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by AB Science SA, H1 2017
  • Pipeline by AstraZeneca Plc, H1 2017
  • Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Pipeline by ValiRx Plc, H1 2017
  • Pipeline by Zen-Bio Inc, H1 2017
  • Dormant Projects, H1 2017
  • Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top